Skip to Content

Press Releases

Intec Pharma to Participate in BioCentury's 24th Annual NewsMakers in the Biotech Industry Conference

September 1, 2017 at 8:00 AM EDT

JERUSALEM, September 1, 2017 /PRNewswire/ --

Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in BioCentury's 24th Annual NewsMakers in the Biotech Industry Conference to be held on September 8, 2017 at the Millennium Broadway Hotel & Conference Center in New York City.  

Date and Time of Presentation: Friday, September 8, 2017 at 10:30 a.m. Eastern time

Venue: Millennium Broadway Hotel & Conference Center

Format: Company presentation

Presenter: John Kozarich, Ph.D., Chairman of the Board of Intec Pharma

Dr. Kozarich's presentation will be webcast live and can be accessed on the Investor Relations section of the Company's website at http://www.intecpharma.com.  

About Intec Pharma Ltd. 

Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's product pipeline includes two product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is being developed for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC), which is being developed for various indications including low back neuropathic pain and fibromyalgia.

Contacts:
Jeffrey A. Meckler
Chief Executive Officer
Intec Pharma Ltd.
+1-646-374-8050
jeffrey@intecpharma.com  

Anne Marie Fields
Senior Vice President
LHA Investor Relations
+1-212-838-3777
afields@lhai.com

 

SOURCE Intec Pharma Ltd.

 

Source: PR Newswire (September 1, 2017 - 8:00 AM EDT)